Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 2018 Apr;24(4):827-831
Date
11/21/2017Pubmed ID
29155319Pubmed Central ID
PMC5902644DOI
10.1016/j.bbmt.2017.11.003Scopus ID
2-s2.0-85039061191 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Even in the modern era of targeted therapies, allogeneic hematopoietic stem cell transplantation (allo-HCT) can offer a chance of extended survival in B cell non-Hodgkin lymphoma (B-NHL) patients who relapse after or are deemed ineligible for autologous transplantation. A better understanding of the factors influencing the graft-versus-lymphoma (GVL) response would be useful in identifying B-NHL patients who may benefit from allo-HCT. Based on prior single-center reports, we hypothesized that certain HLA alleles, or haplotypes, may be associated with superior GVL compared with others after allo-HCT. To test this possibility we retrospectively evaluated whether the presence of HLA-A2, HLA-C1C1, HLA-DRB1*01:01, or HLA-DRB1*13 alleles or the presence of HLA-A1+, HLA-A2-, and HLA-B44- haplotypes is associated with outcomes in a cohort of 1314 HLA-8/8 matched sibling or unrelated donor HCT for relapsed/refractory B-NHL. We observed no significant association between any HLA allele or haplotype and overall survival or any of the secondary endpoints. In conclusion, this study represents the largest reported series of allo-HCT outcomes of B-NHL patients based on HLA type. Identification of other variables will be required to delineate the immunologic impact of donor-host interactions on outcomes of allo-HCT for B-NHL.
Author List
William BM, Wang T, Haagenson MD, Fleischhauer K, Verneris M, Hsu KC, de Lima MJ, Fernandez-ViƱa M, Spellman SR, Lee SJ, Hill BTAuthor
Tao Wang PhD Professor in the Data Science Institute department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Alleles
Allografts
Disease-Free Survival
Female
Graft vs Tumor Effect
HLA Antigens
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, B-Cell
Male
Middle Aged
Retrospective Studies
Siblings
Survival Rate
Unrelated Donors